Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation.
BACKGROUND
Unimpaired HLA class I antigen presentation is a prerequisite for the recognition of tumor cells by cytotoxic T lymphocytes and thus essential for the success of anticancer immunotherapeutic concepts. Several approaches have been taken in the immunotherapy of metastatic renal cell carcinoma (RCC), however of limited success. HLA loss or down-regulation have often been reported and might interfere with immunotherapeutic approaches aimed at the recognition of HLA-presented peptides.


METHODS
We employed a quantitative method of molecular analysis for the comparison of HLA amounts on primary tumor, normal kidney and metastases of RCC, using Edman degradation. We analyzed a series of 47 RCC samples including corresponding renal parenchyma, local lymph node metastases and distant metastases.


RESULTS
Results of quantitative Edman degradation revealed significantly higher HLA yields on primary tumor and metastases compared to normal kidney tissue. This effect was shown not to result from infiltrating immune cells, since tumor-infiltrating lymphocytes had no influence on the overall HLA recovery from tumor tissue. Unexpectedly, we found a higher amount of HLA class I molecules on distant metastases compared to local lymph node metastases.


CONCLUSIONS
Edman degradation allows the direct quantitative comparison of HLA class I protein expression by tumor or normal tissue and metastases of RCC patients. Our results raise hopes for improving the success and effectiveness of future immunotherapeutic concepts for metastatic RCC.
Department of Immunology, Institute for Cell Biology, University of Tübingen, Germany.
Juliane S
JS
Stickel
Natalie
N
Stickel
Jörg
J
Hennenlotter
Karin
K
Klingel
Arnulf
A
Stenzl
Hans-Georg
HG
Rammensee
Stefan
S
Stevanović
D000595:Amino Acid Sequence; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000556:secondary*; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000556:secondary*; D008969:Molecular Sequence Data; D009943:Organophosphorus Compounds / Q000737:chemistry; D020539:Sequence Analysis, Protein / Q000379:methods
C043517:2-(4-isothiocyanatophenoxy)-1,3,2-dioxaphosphinene 2-oxide; D006680:HLA Antigens; D009943:Organophosphorus Compounds
J Biomol Tech. 2007 Dec;18(5):306-20
18166674
Eur Urol. 2009 Jun;55(6):1333-42
19201522
Int Rev Cytol. 2007;256:139-89
17241907
Hum Immunol. 2003 Nov;64(11):1081-92
14602239
Semin Cancer Biol. 2002 Feb;12(1):3-13
11926409
Transfus Apher Sci. 2002 Oct;27(2):183-6
12350054
Expert Opin Biol Ther. 2007 Feb;7(2):221-32
17250460
J Immunol. 1995 Jan 15;154(2):567-76
7814868
Am J Pathol. 2003 Feb;162(2):501-8
12547708
Cancer Immunol Immunother. 2008 Nov;57(11):1727-33
18491093
Urology. 1995 Nov;46(5):681-6; discussion 686-7
7495121
Clin Cancer Res. 2006 Mar 15;12(6):1768-75
16551861
Int J Cancer. 2006 Jan 1;118(1):6-10
16003753
Cancer Immunol Immunother. 2009 Sep;58(9):1407-17
19184600
Cancer Sci. 2007 Dec;98(12):1965-8
17919310
Semin Oncol. 2006 Oct;33(5):614-24
17045091
J Urol. 2004 Feb;171(2 Pt 1):885-9
14713847
Cancer Immunol Immunother. 2007 Feb;56(2):227-36
16783578
Expert Rev Anticancer Ther. 2009 Dec;9(12):1817-27
19954293
Tissue Antigens. 2010 Feb;75(2):110-8
19912575
Cancer Res. 2008 Apr 1;68(7):2447-54
18381453
Eur Urol. 2008 Aug;54(2):315-25
18485581
Cancer Res. 2006 Jun 1;66(11):5910-8
16740731
Anal Biochem. 1993 Jul;212(1):212-20
8368496
Science. 1998 Feb 20;279(5354):1166-72
9469799
Biochemistry. 1971 Dec 21;10(26):4912-21
5134536
Nature. 1991 May 23;351(6324):290-6
1709722
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
15674877
Clin Cancer Res. 2006 Aug 1;12(15):4641-4
16899613
Adv Cancer Res. 2001;83:117-58
11665717
J Urol. 2007 Apr;177(4):1269-72; discussion 1272
17382705
Br J Cancer. 1989 Feb;59(2):221-6
2649129
Clin Cancer Res. 2007 Jun 15;13(12):3591-6
17575223
Lancet. 1998 Nov 21;352(9141):1691-6
9853456
Tissue Antigens. 2006 Oct;68(4):303-10
17026465